[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367415-105":59,"doc-detail-367415-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","platelet-to-high-density-lipoprotein-ratio-phr-as-a-predictive-biomarker-for-gastrointestinal-cancers-evidence-from-nhanes","Platelet-to-high-density lipoprotein ratio (PHR) as a predictive biomarker for gastrointestinal cancers - evidence from NHANES","","Gastrointestinal (GI) cancers remain difficult to detect early, especially in low-resource settings, despite advances in diagnosis and treatment. This study evaluates platelet-to-high-density lipoprotein ratio (PHR) as a composite biomarker linking systemic inflammation and lipid metabolism, focusing on its relation to GI cancer risk. Using NHANES 2010–2018 data, elevated PHR shows independent, dose-response association with higher GI cancer risk and stronger effects in older adults, males, and obesity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/platelet-to-high-density-lipoprotein-ratio-phr-as-a-predictive-biomarker-for-gastrointestinal-cancers-evidence-from-nhanes/367415/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/platelet-to-high-density-lipoprotein-ratio-phr-as-a-predictive-biomarker-for-gastrointestinal-cancers-evidence-from-nhanes/367415.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the platelet-to-high-density lipoprotein ratio (PHR), and why is it relevant to GI cancers?","Question",{"text":112,"@type":113},"PHR is calculated as the platelet count divided by high-density lipoprotein cholesterol. It integrates systemic inflammation and lipid metabolism pathways, which are implicated in GI cancer initiation and progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was PHR analyzed in relation to gastrointestinal cancer risk in this study?",{"text":117,"@type":113},"PHR was derived from NHANES 2010–2018 data, categorized into quartiles. Weighted logistic regression, restricted cubic spline modeling, and subgroup analyses assessed associations while adjusting for demographic, socioeconomic, lifestyle, and clinical factors.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about the relationship between PHR and GI cancer risk?",{"text":121,"@type":113},"Higher PHR was independently associated with increased GI cancer risk. Participants in the highest quartile had a significantly higher risk than the lowest quartile, and a dose-response pattern with two inflection points was observed.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367415,1790479022,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Tong and Lou BMCGastroenterology (2025) 25:302  \n[https://doi.org/10.1186/s12876-025-03860-9](https://doi.org/10.1186/s12876-025-03860-9)  \nBMC Gastroenterology  \nRESEARCH Open Access  \nPlatelet-to-high-density lipoprotein ratio (PHR) as a predictive biomarker for gastrointestinal cancers: evidence from NHANES  \nYan Tong 1 and Xiaojun Lou2*  \nAbstract  \nBackground Gastrointestinal (GI) cancers, including gastric, colorectal, and esophageal cancers, pose a significant global health burden. Despite advancements in diagnostic tools, early detection remains challenging, particularly in low-resource settings. Emerging evidence highlights the platelet-to-high-density lipoprotein ratio (PHR) as a novel biomarker integrating systemic inflammation and lipid metabolism. However, its association with GI cancer risk remains underexplored.  \nMethods This study utilized data from the National Health and Nutrition Examination Survey (NHANES) from 2010 to 2018, comprising 19,388 participants, including 230 with GI cancers. PHR was calculated as the ratio of platelet count to high-density lipoprotein cholesterol levels and categorized into quartiles. Weighted logistic regression models, restricted cubic spline analysis, and subgroup analyses were employed to evaluate the association between PHR and GI cancer risk, adjusting for demographic, socioeconomic, lifestyle, and clinical factors.  \nResults Elevated PHR was independently associated with an increased risk of GI cancers. Participants in the highest PHR quartile exhibited a significantly higher risk (adjusted OR = 3 . 09; 95% CI: 2 .16–4.43) compared to the lowest quartile. A dose-response relationship was observed, with two critical inflection points at PHR values of 3.2 and 4.5. Subgroup analyses revealed stronger associations among older adults, males, and obese individuals. The findings suggest that PHR may reflect the dynamic balance of systemic inflammation and lipid metabolism, contributing to tumorigenesis.  \nConclusion This study identifies PHR as a promising, cost-effective biomarker for early detection and risk stratification of GI cancers. Its integration into screening programs could improve precision medicine strategies by identifying high-risk individuals for early intervention. Further longitudinal and mechanistic studies are warranted to confirm these findings and explore the underlying biological mechanisms.  \nKeywords Platelet-to-high-density lipoprotein ratio (PHR), Gastrointestinal cancers, Lipid metabolism, NHANES, Cancer screening, Dose-response relationship  \n*Correspondence: Xiaojun Lou [lou.xj.01@163.com](lou.xj.01@163.com)  \n1Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China 2Department of Gastroenterology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nTong and Lou BMC Gastroenterology (2025) 25:302  \nIntroduction  \nGastrointestinal (GI) cancers, including g","cbCaiaBT4RmvDJiY","https://ap.wps.com/l/cbCaiaBT4RmvDJiY","pdf",1867428,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the platelet-to-high-density lipoprotein ratio (PHR), and why is it relevant to GI cancers?\",\"answer\":\"PHR is calculated as the platelet count divided by high-density lipoprotein cholesterol. It integrates systemic inflammation and lipid metabolism pathways, which are implicated in GI cancer initiation and progression.\"},{\"question\":\"How was PHR analyzed in relation to gastrointestinal cancer risk in this study?\",\"answer\":\"PHR was derived from NHANES 2010–2018 data, categorized into quartiles. Weighted logistic regression, restricted cubic spline modeling, and subgroup analyses assessed associations while adjusting for demographic, socioeconomic, lifestyle, and clinical factors.\"},{\"question\":\"What were the key findings about the relationship between PHR and GI cancer risk?\",\"answer\":\"Higher PHR was independently associated with increased GI cancer risk. Participants in the highest quartile had a significantly higher risk than the lowest quartile, and a dose-response pattern with two inflection points was observed.\"}]","Platelet-to-high-density lipoprotein ratio (PHR) as a predictive biomarker for gastrointestinal cancers - evidence from NHANES | PDF",1790170684,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcf98929a6dce155720cb6dd19b05fe1.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a494940e8fbb55eaefc3098526d3bd6.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b1af4ff75ec7ef32cb43f887413307a.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e789b1a3ec068a997d9e1f56771cf7fe.webp",980,1306]